SRRK News and Press, Scholar Rock Holding Corporation From 03/19/24

Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...

2024-03-05 07:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Katie Pe...

2024-02-06 15:27:22 ET More on Veru Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha For further details see: Veru eyes better weight loss drugs as ...

Preclinical findings presented at Keystone Symposia show lean mass preservation, fat mass loss, and improved glucose metabolism Scholar Rock’s novel myostatin inhibitor, SRK-439, is part of its growing, industry-leading portfolio of innovative, highly selective anti-myostatin treat...

SRK-439 is a novel selective myostatin inhibitor designed for the treatment of cardiometabolic disorders Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical c...

Randomized Phase 2 proof-of-concept trial with apitegromab in patients with obesity on GLP-1 therapies on track to initiate mid-2024 Study aims to show the importance of selective myostatin inhibition in preservation of lean muscle mass as part of healthy, safe weight loss management ...

2024-01-12 05:32:53 ET Summary Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustaine...

2024-01-04 13:17:57 ET More on Scholar Rock Scholar Rock Holding Corporation (SRRK) Q3 2023 Earnings Call Transcript Scholar Rock Holding Corporation 2023 Q3 - Results - Earnings Call Presentation Scholar Rock: SMA Data Readout In 2024 Makes This Worth A Look ...